FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks – CNBC

February 27, 2023 by quixnet

FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risksCNBC
FDA flags Guillain-Barré risks for GSK, Pfizer RSV shots, but just one will need safety trialFierceBiotech
FDA Panel Backs Pfizer’s RSV Vaccine for Older AdultsMedpage Today
Pfizer, BioNTech Submit sBLA for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 VaccinePharmacy Times